185 related articles for article (PubMed ID: 16800173)
1. [Skin signs associated with epidermal growth factor inhibitors].
Hannoud S; Rixe O; Bloch J; Le Pelletier F; Lebrun-Vignes B; Doarika A; Khayat D; Chosidow O
Ann Dermatol Venereol; 2006 Mar; 133(3):239-42. PubMed ID: 16800173
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
3. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
[TBL] [Abstract][Full Text] [Related]
4. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
5. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
6. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
Santiago F; Gonçalo M; Reis JP; Figueiredo A
An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
[TBL] [Abstract][Full Text] [Related]
7. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
8. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
9. EGFR inhibitor-induced cut-like skin lesions of the fingers.
Iskandar AS; Hwang A; Dasanu CA
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30068575
[TBL] [Abstract][Full Text] [Related]
10. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Zhao Q; Wang YN; Wang B
Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
Bellini V; Bianchi L; Pelliccia S; Lisi P
J Cutan Pathol; 2016 Mar; 43(3):211-8. PubMed ID: 26423594
[TBL] [Abstract][Full Text] [Related]
12. Folliculotropic Cutaneous Metastases and Lymphangitis Carcinomatosa: When Cutaneous Metastases of Breast Carcinoma Are Mistaken for Cutaneous Infections.
Paolino G; Panetta C; Didona D; Donati M; Donati P
Acta Dermatovenerol Croat; 2016 Jun; 24(2):154-7. PubMed ID: 27477179
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
Braden RL; Anadkat MJ
Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
[TBL] [Abstract][Full Text] [Related]
14. [Acneiform eruption secondary to cetuximab].
Herrera-Acosta E; Martín-Ezquerra G; Iglesias M; Umbert P
Actas Dermosifiliogr; 2005 May; 96(4):252-4. PubMed ID: 16476378
[TBL] [Abstract][Full Text] [Related]
15. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
[TBL] [Abstract][Full Text] [Related]
16. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Hollywood E
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Fernández-Guarino M; Pérez García B; Aldanondo Fernández de la Mora I; García-Millán C; Garrido López P; Jaén Olasolo P
Actas Dermosifiliogr; 2006 Oct; 97(8):503-8. PubMed ID: 17067527
[TBL] [Abstract][Full Text] [Related]
19. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
Gencoglan G; Ceylan C
Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
[TBL] [Abstract][Full Text] [Related]
20. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.
Reguiai Z; Bachet JB; Bachmeyer C; Peuvrel L; Beylot-Barry M; Bezier M; Boucher E; Chevelle C; Colin P; Guimbaud R; Mineur L; Richard MA; Artru P; Dufour P; Gornet JM; Samalin E; Bensadoun RJ; Ychou M; André T; Dreno B; Bouché O
Support Care Cancer; 2012 Jul; 20(7):1395-404. PubMed ID: 22539049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
